Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Finished Goods (2017 - 2019)

Ironwood Pharmaceuticals' Finished Goods history spans 3 years, with the latest figure at $191000.0 for Q4 2019.

  • On a quarterly basis, Finished Goods changed N/A to $191000.0 in Q4 2019 year-over-year; TTM through Dec 2019 was $191000.0, a N/A change, with the full-year FY2019 number at $191000.0, changed N/A from a year prior.
  • Finished Goods hit $191000.0 in Q4 2019 for Ironwood Pharmaceuticals, down from $457000.0 in the prior quarter.
  • Over the last five years, Finished Goods for IRWD hit a ceiling of $1.4 million in Q1 2018 and a floor of $76000.0 in Q3 2018.
  • Historically, Finished Goods has averaged $589428.6 across 3 years, with a median of $479000.0 in 2017.
  • Biggest five-year swings in Finished Goods: crashed 84.13% in 2018 and later surged 501.32% in 2019.
  • Tracing IRWD's Finished Goods over 3 years: stood at $735000.0 in 2017, then tumbled by 89.66% to $76000.0 in 2018, then surged by 151.32% to $191000.0 in 2019.
  • Business Quant data shows Finished Goods for IRWD at $191000.0 in Q4 2019, $457000.0 in Q3 2019, and $76000.0 in Q3 2018.